Efficacy of split-dosing versus nonsplit-dosing of ergocalciferol on serum 25-hydroxyvitamin D in chronic kidney disease patients
Not Applicable
Recruiting
- Conditions
- vitamin D def/insuff in chronic kidney disease patients
- Registration Number
- TCTR20190830003
- Lead Sponsor
- Phramongkutklao Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 76
Inclusion Criteria
1. Patients with chronic kidney disease stage 3-5 before dialysis
2. Patients aged 18 - 80 years old
3. Level 25 (OH) D in the blood, less than 30 ng / mL
Exclusion Criteria
1 patients who have been diagnosed as primary or tertiary hyperparathyroidism
2 Patients who have previously received vitamin D ergocalciferol
3 Patients receiving active form of vitamin D
4 Blood calcium levels greater than 10.5 mg / dL
5 Blood phosphate levels greater than 5.5 mg / dL
6 Cancer
7 Chronic diseases expected to die within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum 25-hydroxyvitamin D 12 wk To compare the efficacy in blood levels 25-hydroxyvitamin D after oral ergocalciferol treatment in
- Secondary Outcome Measures
Name Time Method serum parathyroid hormone calcium phosphate 12 wk To study the level of changes in calcium phosphate and parathyroid hormones in the blood after oral ,side effect 12 wk To study the rate of side effects of treatment ergocalciferol Oral intake in divided and non-divide